The Transcellular Spread of Cytosolic Amyloids, Prions, and Prionoids  by Aguzzi, Adriano & Rajendran, Lawrence
Neuron
PerspectiveThe Transcellular Spread of Cytosolic Amyloids,
Prions, and PrionoidsAdriano Aguzzi1,* and Lawrence Rajendran2,*
1Institute of Neuropathology, University Hospital of Zu¨rich, Schmelzbergstrasse 12, CH-8091 Zu¨rich, Switzerland
2Systems and Cell Biology of Neurodegeneration, Psychiatry Research, University of Zurich, CH-8008 Zu¨rich, Switzerland
*Correspondence: adriano.aguzzi@usz.ch (A.A.), rajendran@bli.uzh.ch (L.R.)
DOI 10.1016/j.neuron.2009.12.016
Recent reports indicate that a growing number of intracellular proteins are not only prone to pathological
aggregation but can also be released and ‘‘infect’’ neighboring cells. Therefore, many complex diseases
may obey a simplemodel of propagationwhere the penetration of seeds into hosts determines spatial spread
and disease progression. We term these proteins prionoids, as they appear to infect their neighbors just like
prions—but how can bulky protein aggregates be released from cells and how do they access other cells?
The widespread existence of such prionoids raises unexpected issues that question our understanding of
basic cell biology.Imagine that you are a neuroscientist vacationing on Mars. One
day you encounter a colony of Martians that, as it happens, look
similar to water bottles. The Martians are highly distressed and
seek your advice, as their community is plagued by an enigmatic
transmissible disease. Intrigued, you agree to help. It turns out
that the bodies of your exobiotic friends consist of bottles filled
with a supersaturated salt solution. At some point crystals
have started forming in one individual, and then crystallization
has somehow been transferred to other community members.
Lacking molecular insight, you would initially conclude that the
Martians are affected by an infectious agent. Through ingenuity
and technology, you may then discover that the infectious agent
is exceedingly simple and homogeneous, that it lacks informa-
tional nucleic acids, and that it is generated both by ordered
aggregation of an intrinsic precursor and by appositional growth
of extrinsically added seeds. Your discovery will earn you the
Intergalactic Nobel Prize, yet two crucial questions remain unan-
swered: how do the crystals transfer between individuals, and
what can be done to prevent this from happening?
Middle-aged readers may feel reminded of the plot for
Andromeda Strain, a stunningly prescient novel published in
1969 by the late Michael Crichton. But the sci-fi scenario
described above is also the blueprint of Prusiner’s hypothesis
of prion propagation. Over time, we have learned that prions
consist of PrPSc, higher-order aggregates of a physiological
protein termed PrPC. Accordingly, prions propagate through
elongation and breakage of PrPSc aggregates (Aguzzi and Poly-
menidou, 2004)—not unlike the crystals vexing our extraterres-
trial friends.
There is mounting evidence (Clavaguera et al., 2009; Frost
et al., 2009; Ren et al., 2009; Desplats et al., 2009; Luk et al.,
2009) suggesting that the events sketched above, far from being
confined to science-fiction and prion diseases (whose incidence
in humans is just z1/106/year), may underlie highly prevalent
human diseases of the brain and many other organs. The unifying
characteristics of all these diseases is the aggregation of
proteins into highly ordered stacks, henceforth termed
‘‘amyloids’’ irrespective of their size. Since PrPSc undoubtedlyfulfills the latter definition of amyloid, one is led to wonder
whether the prion principle may be much more pervasive than
previously appreciated and whether many more diseases of
unknown cause may eventually turn out to rely on prion-like
propagation (Table 1, upper panel). Even more intriguingly,
a number of proteins appear to exert normal functions when
arranged in highly ordered stacks that are similar to amyloids
and to prionoids (Table 1, lower panel).
Prions and Prionoids
There is one crucial difference between bona fide prion diseases
and all other amyloids and prion-like phenomena hitherto
described in uni- and pluricellular organisms (Table 1). Prions
are infectious agents, transmissible between individuals, and
tractable with microbiological techniques—including, e.g., titer
determinations. Even if certain amyloids of yeast and mammals
appear to infect neighboring molecules and sometimes neigh-
boring cells, they do not propagate within communities, and
none of them were found to cause macroepidemics such as
Kuru and bovine spongiform encephalopathy. We have therefore
termed these self-aggregating proteins ‘‘prionoids’’ (Aguzzi,
2009), since the lack of microbiological transmissibility
precludes their classification as true prions.
Some prionoids may soon qualify for an upgrade to prion
status. At least in select settings, amyloid A (AA) amyloidosis
may exist as a truly infectious disease based on a self-propa-
gating protein. AA amyloid consists of orderly aggregated frag-
ments of SAA protein, whose deposition can damage many
organs of the body. Somewhat bizarrely, AA aggregation is
also present in the liver of force-fed geese, hence contributing
to the pathophysiology of foie gras (Solomon et al., 2007). AA
seeds can induce amyloidosis upon transfer of white blood cells
(Sponarova et al., 2008). Furthermore, AA seeds are excreted
with the feces, and AA amyloidosis is endemic in populations
of cheetah (Zhang et al., 2008). It is therefore tantalizing to
suspect that amyloid may entertain the complete life cycle of
an infectious agent, including transmission by the orofecal and
hematogenous route—similarly to enteroviruses and, perhaps,Neuron 64, December 24, 2009 ª2009 Elsevier Inc. 783
Table 1. Potential Prionoids in Health and Disease (Adapted from Aguzzi, 2009)
Phenotype/Function Protein Molecular Transmissibility Bona Fide Infectivity
Prion diseases PrPSc (luminal) yes yes
Alzheimer’s disease Ab (luminal) yes in APP-overexpressing mice
Tauopathies Tau (cytosolic) possibly not shown
Parkinson’s disease a-synuclein (cytosolic) host-to-graft not shown
AA amyloidosis SAA (luminal) yes probable
Huntington’s disease PolyQ (nuclear) yes not shown
Suppressed translational termination (yeast) Sup35 yes limited
Biofilm production (bacteria) bacterial curlin yes questionable
Heterkaryon incompatibility (fungi) Het-s yes limited
Pituitary secretory granules peptide hormones not shown not shown
Mammalian skin pigmentation Pmel17 not shown not shown
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avoid foie gras, including, e.g., animal welfare concerns, gour-
mets may not need to panic: under experimental conditions,
AA amyloidosis is only transmitted to AgNO3-pretreated mice
that display elevated levels of the SAA precursor protein.
Alzheimer’s disease (AD) has long been suspected to be
a transmissible disease, but these suspicions have never mate-
rialized in epidemiological studies. On the other hand, Mathias
Jucker and Lary Walker observed that injection of the Ab peptide
from human AD brains induced robust and convincing aggrega-
tion of Ab in transgenic mice overexpressing the Ab precursor
protein, APP (Kane et al., 2000; Meyer-Luehmann et al., 2006).
Jucker’s finding raises an epistemologically significant question:
if aggregation depends on the introduction of seeds and on the
availability of the monomeric precursor, and if amyloid repre-
sents the primordial state of all proteins (Chiti and Dobson,
2006), wouldn’t all proteins—under appropriate conditions—
give rise to prionoids in the presence of sufficient precursor?
The issues sketched above go well beyond AD and prions.
There are many other diseases—not necessarily involving the
nervous system—whose pathogenesis involves ordered aggre-
gation of proteins, but for which there is no evidence of transmis-
sion between individuals. The best-studied of these are the
systemic amyloidoses, which come about through the nucle-
ation of some aggregation-prone proteins such as transthyretin
and immunoglobulin light chains. Yet ordered protein aggrega-
tion is by no means confined to the ‘‘classical’’ amyloidoses
and extends to a number of conditions, some of which have
been rather unexpected.
Type II diabetes is yet another disease whose pathogenesis
may involve ordered protein aggregation. Evidence to support
this idea was discovered over a century ago (Opie, 1901) but
was largely forgotten until recently. It is now evident that aggre-
gation of islet amyloid polypeptide (IAPP) is an exceedingly
frequent feature of type II diabetes. IAPP amyloids damage the
insulin-producing b cells within pancreatic islets and may
crucially contribute to the pathogenesis of diabetes (Hull et al.,
2004). It is unknown, however, whether IAPP deposition simply
accrues linearly with IAPP production or whether it spreads
prion-like from one pancreatic islet to the next.
A body of recent work supports the idea that many aggrega-
tion proteinopathies are, in one way or another, transmissible.784 Neuron 64, December 24, 2009 ª2009 Elsevier Inc.A recent report showed that a-synuclein is released from
neurons and is then taken up by the neighboring cells, thereby
aiding in a progressive spread of the protein (Desplats et al.,
2009; Lee et al., 2005). When exogenously added to cultured
cells, fluorescently labeled, recombinant a-synuclein was inter-
nalized from the extracellular milieu into the cytosol. Further-
more, injection of GFP-labeled mouse cortical neuronal stem
cells into the hippocampus of a-synuclein-transgenic mice led
to the efficient uptake of the host a-synuclein into the grafted
cells after just 4 weeks. These findings are reminiscent of the
observation that healthy fetal tissue, grafted into the brains of
Parkinson’s disease patients, acquired intracellular Lewy
bodies. The latter phenomenon is somewhat anecdotal and
has been disputed (Mendez et al., 2008), yet it would be entirely
compatible with the hypothesis that a-synuclein aggregates are
prionoids (Li et al., 2008). A similar study conclusively demon-
strated that exogenous a-synuclein fibrils induced the formation
of Lewy body-like intracellular inclusions in vitro (Luk et al.,
2009). This study also showed that the conversion of the host
cell a-synuclein was accompanied by dramatic changes,
including hyperphosphorylation and ubiquitination of a-synu-
clein aggregates—thus recapitulating some key features of the
human pathology.
In experiments conceptually analogous to those discussed
above, polyglutamine-containing protein aggregates similar to
those present in Huntington’s disease and in spinocerebellar
ataxias exhibited prion-like propagation (Ren et al., 2009). There,
aggregation of huntingtin progressed from the extracellular
space to the cytosol and eventually to the nucleus. What is
more, similar phenomena occurred upon exposure of cells to
Sup35 aggregates, which consist of a yeast protein for which
there are no known mammalian paralogs. This suggests that
the prionoid properties are intrinsic to amyloids and are not
tied to the origin or function of their monomeric precursor
protein.
In another work, Tolnay and colleagues report a similar
phenomenon in a mouse model of ‘‘tauopathy,’’ a neurodegener-
ative disease due to intraneuronal aggregation of the microtu-
bule-associated tau protein (Clavaguera et al., 2009). Aggrega-
tion-prone mutant tau, when extracted from the brain of
transgenic mice, induced tauopathy in mice overexpressing
wild-type tau. Assuming that tau pathology wasn’t elicited by
Neuron
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tangles when exposed to Ab aggregates [Go¨tz et al., 2001]),
these transgenic mice appear to behave like the Martian bottles,
since tauopathy was not induced in mice expressing normal
levels of tau. In yet another study, the microtubule binding part
of the full-length tau was found to attack and penetrate cells
when added exogenously, and this again induced host tau mis-
folding (Frost et al., 2009). This study also showed that aggre-
gated intracellular Tau spontaneously transferred between two
cocultured cell populations (Frost et al., 2009). In the case of
both tau and polyglutamines, the protein aggregates appear to
gain access to the cytosol and to cause further aggregation of
their host counterparts—presumably by nucleation.
The unifying characteristics of all these diseases is the aggre-
gation of proteins into highly ordered stacks, termed amyloids ir-
respective of their size; the growth of these structures also
exhibits generic features (Knowles et al., 2009) shared with
a wide class of self-assembly phenomena characterized by elon-
gation and fragmentation, such as the formation of analogous
aggregates in micro-organisms and in vitro. Two conclusions
can be drawn from the recent studies: (1) an unexpected number
of amyloidogenic proteins can be released from affected cells
in the form of extracellular amyloid seeds, and (2) even more
surprisingly, these seeds can then re-enter other cells and
nucleate the aggregation of their intracellular counterparts—in
the cytosol or even in the nucleus. The biological and practical
implications are far-reaching. On the one hand, cell therapies
of aggregation diseases may be more difficult than anticipated,
as the transplanted cells may undergo infection. A possible
remedy could consist in the removal of the genes encoding the
precursor of the offending proteins from the cells utilized for
therapy—e.g., using the zinc-finger nuclease strategy (Hocke-
meyer et al., 2009). On the other hand, a novel paradigm of
amyloid pathogenesis is emerging from these data, whereby
each prionoid behaves as a self-assembling and self-replicating
nanomachine.
Conversely, these findings raise a number of enigmas for
which we are lacking any satisfactory answer. Whereas PrPC
and the Ab are luminally exposed, a-synuclein and tau are cyto-
plasmic—and huntingtin is even nuclear. Aggregates of both Ab
and PrPSc, as well as their monomeric precursors, are found in
the extracellular space; it is hence intuitive that the nucleation
process can propagate spatially across large distances. Instead,
the propagation of cytoplasmic prionoids challenges our basic
cell-biological understanding, since it posits that protein aggre-
gates are released into the extracellular space and can subse-
quently reenter—and wreak havoc—in the cytosol of other cells.
The release of cytosolic amyloids is supported by the ameliora-
tion of Lewy body pathology in a-synuclein transgenic mice
immunized with human a-synuclein (Masliah et al., 2005). Simi-
larly, anti-tau oligomer immunotherapy reduced brain pathology
(Asuni et al., 2007), and immunization with mutant SOD1 led to
clearance of SOD1 and delayed the onset of the disease in
mice (Urushitani et al., 2007). All of these results indicate that
cytosolic amyloids are somehow accessible to extracellular anti-
bodies. This raises the question of how these proteins are
released into the extracellular space (‘‘cytosol to lumen’’) and
how they subsequently re-enter cellular cytosol (‘‘lumen tocytosol’’). Both events require trespassing lipid bilayer
barriers—by no means a trivial feat for proteins, let alone high-
molecular-weight aggregates.
Release of Cytosolic Prionoids from Cells
The release of cytosolic proteins into the extracellular milieu is by
no means an exclusive feature of amyloids. While most secreted
proteins follow the conventional ER-Golgi biosynthetic pathway,
several proteins have been reported to be secreted through
a noncanonical pathway (Muesch et al., 1990; Nickel, 2003;
Prudovsky et al., 2003). These proteins often lack a patent secre-
tory signal sequence, and their release is not dependent on the
intact ER/Golgi machinery. Prominent examples include the
proangiogenic molecule, fibroblast growth factor-1 (Jackson
et al., 1995; Mandinova et al., 2003; Prudovsky et al., 2002)
and -2 (Engling et al., 2002; Mignatti et al., 1992), IL-1b (Andrei
et al., 1999; Rubartelli et al., 1990), annexins, migration inhibitory
factor1 (Flieger et al., 2003), galectins (Cleves et al., 1996;
Cooper and Barondes, 1990; Lutomski et al., 1997), and caspase
1. While no single key mechanism has been documented for their
exit from the cytoplasm, each of the following pathways dis-
cussed may potentially contribute to this phenomenon.
Direct Translocation at the Plasma Membrane
Transport of proteins across the plasma membrane via trans-
porter complexes is uncommon, but not unheard of. Perhaps
the only conclusive evidence for this type of translocation across
the membrane has been shown for the growth factor FGF-2
(Scha¨fer et al., 2004). Reconstitution assays in inside-out vesi-
cles (extracellular side inside and cytoplasm outside) indicate
that cytosolic FGF-2 can directly translocate to the extracellular
compartment in a temperature- and time-dependent manner.
This translocation is also exhibited by galectin-1, but not by
FGF-4 protein or MIFs, suggesting a certain degree of specificity.
Polypeptides are transported across the endoplasmic reticulum
bilayer by the Sec61 translocon and—in the opposite direction—
by the retrotranslocon machinery (Lilley and Ploegh, 2004): one
might therefore posit the existence of analogous transporters
embedded in the plasma membrane.
Could cytoplasmic prionoids utilize such hypothetical trans-
porters? Both a-synuclein and huntingtin can interact with acidic
phospholipids enriched on the cytoplasmic leaflet (Kegel et al.,
2005, 2009; van Rooijen et al., 2008) and have been proposed
to form pores or conducting channels (Figure 1). However, the
precise mechanics of this type of secretion remains mysterious.
Although the interaction of aggregates with lipids has been
documented to occur in protein-free liposomes, its importance
for translocation across biological membranes remains unclear.
Apoptotic Blebs and Microvesicles
Apoptotic blebs are subcellular micelles that are released by
dying cells and may encapsulate significant amounts of cytosol
(Figure 1) (Cocucci et al., 2009). Whether there is a general incor-
poration of cytosolic proteins or there is specificity in the nature
of proteins that undergo encapsulation is not yet clear. Rigorous
proteomic analysis could address this issue (Alcazar et al., 2009).
While similar to blebs in size and content, microvesicles are
formed in healthy cells by outward budding of the plasmaNeuron 64, December 24, 2009 ª2009 Elsevier Inc. 785
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viruses. FGF-2 was also found in microvesicles (Taverna et al.,
2003), as was capsase-1, another protein that is secreted via
a non ER-Golgi pathway. Interestingly, caspase-1 itself is
involved in the secretion of several cytosolic proteins by a mech-
anism that is poorly understood (Keller et al., 2008; Pe´trilli et al.,
2007). Caspase-1 silencing by RNAi or its pharmacological inhi-
bition inhibits the secretion of several cytosolic proteins,
including galectins, fgf-1 and -2, MIfs, and IL1-a and -b (Keller
et al., 2008). Experiments with small-molecule inhibitors suggest
that the proapoptotic function of caspase-1 or its proteolytic
activity is essential for the secretion. The critical factor that
enables secretion upon cleavage and activation by caspase is
still unknown: its identification will definitely shed light on the
mechanism by which cytosolic proteins are secreted.
Release through the Exosome Shuttle
Several cytosolic proteins, including alix, enolase, heat shock
proteins, caspase-1, and galectin, are released via exosomes
(Mathivanan et al., 2009; Olver and Vidal, 2007; Wubbolts
et al., 2003). Although exosomes are mostly implicated in the
sorting and release of membrane proteins, they also carry
a substantial amount of cytosol. During endocytosis, the plasma
membrane invagination (outside-in) gives rise to early endo-
somes, the limiting membrane of which undergoes another
round of invagination (inside-out) to form the intraluminal vesi-
cles, which give the endosome a multivesicular appearance.
Upon invagination, these intraluminal vesicles encapsulate cyto-
solic material. Multivesicular bodies harboring the intraluminal
vesicles can now fuse with the plasma membrane to release
these ILVs as exosomes. This also explains the topology of exo-
somes being identical to that of the plasma membrane (outside-
out; inside-in) with the cytosol encapsulated within them (Fig-
ure 1). By taking the exosome shuttle—but also by hijacking
blebs and microvesicles—protein aggregates may depart from
their cells of origin without the need to cross any membrane.786 Neuron 64, December 24, 2009 ª2009 Elsevier Inc.Both microvesicles and exosomes are
found in plasma and other body fluids,
suggesting that these fluids may act as
vectors for prionoids.
Exosomes deserve special consider-
ation because of their relevance to
neurodegeneration. Luminally exposed
amyloid-forming proteins, such as Ab
and PrP, are both secreted on exosomal
vesicles, and this association has been
implicated in disease progression and
pathogenesis. Amyloidogenic processing
of amyloid precursor protein by b- and
g-secretase generates Ab peptide in early
endosomes (Rajendran et al., 2006), traf-
ficked to multivesicular bodies (Rajen-dran, et al., 2007), and is then released from the cells via exo-
somes. Both PrPC and the infectious PrPSc are also trafficked
in cells via multivesicular bodies and are associated with exo-
somes (Fevrier et al., 2004; Veith et al., 2009). Since amyloid
b peptide and prion release have pathological consequences,
it is possible that exosomes function as Trojan horses facilitating
the release of these pathogenic peptides and playing a role in
disease progression (Rajendran, et al., 2007). Perhaps aggre-
gates of a-synuclein, tau, and huntingtin could be transported
inside exosomal vesicles for long-range signaling or deposition.
Moreover, exosomal vesicles contain lipids that drive fibrillation
and mediate accelerated amyloid formation (Yuyama et al.,
2008).
Autophagy, by which certain cytosolic proteins are engulfed,
may also influence exosome secretion (Fader et al., 2008), yet
whether autophagy regulates the release of cytosolic proteins
remains to be seen. The uptake of exosomes and exosome-
capsulated proteins could shuttle proteins between cells, as
recently observed for the transfer of Wnt protein between
synapses via exosome-like vesicles (Korkut et al., 2009).
Discharge of Aggregates through Pores
Biophysical studies of membrane lipid-Ab interactions suggest
that Ab peptides can form pores on the membrane (Kayed
et al., 2004, 2009; Lashuel et al., 2002). These pores can mediate
the leakage of ions and small molecules. a-synuclein and hun-
tingtin were also found to interact with membrane lipids and
form pores at the membrane akin to those mediating the entry
of toxins into the cytosol (Georgieva et al., 2008; Zhu et al.,
2003). Lipid association or membrane anchoring of these
peptides may drive their oligomerization and, ultimately, pore
formation (van Rooijen et al., 2009). However, these pores are
thought to be similar to ion channels, and it is not trivial to
envisage how they could eject such large protein aggregates.
On a more practical note, the findings that cytosolic amyloids
may be released from cells raise the intriguing possibility that the
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brospinal fluid (CSF). If so, they could serve as biomarkers of
disease progression. In fact, CSF tau is a relatively sensitive
though unspecific biomarker of AD (Blennow and Hampel,
2003), probably because it is released by dying neurons. In the
light of these new findings, one could imagine that aggregated
tau and other cytosolic amyloids could also be released from
cells in a regulated way without neuronal death. Further work is
required to assess whether other cytosolic amyloid proteins
such as SOD1 (involved in amyotrophic lateral sclerosis or
ALS) and TDP-43 (in frontotemporal dementias and ALS) are
also released and nucleate their siblings in foreign cells. Indeed,
antibodies against intracellular proteins are detected in Alz-
heimer’s disease. Regulated exocytic release of these proteins
could explain their presence in the CSF and, in some cases, in
the plasma of the affected individuals.
Internalization: The Arduous Path of External
Aggregates into the Cytosol
If the externalization of protein aggregates presents an inter-
esting quiz, their internalization and the subsequent nucleation
of cytosolic proteins in target cells is even more puzzling. If prio-
noids are internalized through endosomes, the limiting
membrane of the endosomes poses a barrier for these proteins
to diffuse across the bilayer into the cytosol. In the following, we
review few examples of extracellular proteins ending up in the
cytosol.
Direct Penetration of the Plasma Membrane
Peptides derived from viral proteins (HIV-tat, HSV-VP22) and
Antennapedia proteins have been documented to have cell-
penetrating activity (Elliott and O’Hare, 1997; Frankel and
Pabo, 1988), and this has been utilized to target drugs to cyto-
solic compartments (Rajendran et al., 2009). While the mecha-
nism of cell penetration is still poorly understood, interactions
of peptides with positively charged phospholipids are thought
to induce a conformational change that allows the passage of
these peptides through the bilayer (Wender et al., 2000). It is
theoretically possible that prionoids gain access to the cyto-
plasm via such a mechanism, but it is difficult to imagine that
high-molecular-weight aggregates would avail themselves of
this pathway.
Release from the Endosomes by Endo-Osmolysis
or Endosomal Fusion
Certain bacterial toxins such as diphtheria and cholera toxins
bind to their receptors at membrane from the extracellular
side, traffic to the endosomes or Golgi, and enter the cytosol
(Johannes and Decaudin, 2005). It is within this compartment
that they gain access to their targets—a property that can be ex-
ploited by conjugating drugs to the ligands/toxins (Rajendran
et al., 2009). Enveloped viruses, on the other hand, deliver their
genome to the cytosol (and in some cases to the nucleus) by
either fusing their envelopes with the plasmalemmal or endoso-
mal membrane or by releasing their contents by pore formation
in endosomes (endosomal fusion) (Leopold and Crystal, 2007).
The influenza virus carries a fusogenic peptide sequence at the
N terminus of viral hemagglutinin, which allows the virus tofuse with the endosomal membrane. Other pathogen-associ-
ated proteins, such as diphtheria toxin, colonize the cytosol by
disrupting endosomal membranes (endo-osmolysis) (Huang
et al., 2003).
It is not inconceivable that prionoids possess the properties
demonstrated by other pathogens, as outlined above, but it is
also possible that binding to cationic phospholipids at endoso-
mal pH triggers their entry into the cytosol. Lee and colleagues
showed that a-synuclein is internalized in endosomes via a dyna-
min-1-dependent pathway (Desplats et al., 2009), but how
a-synuclein leaves the endosome is shrouded in mystery.
Once in the cytosol, these nuclei may elongate, fracture, and
produce further nuclei—ultimately promoting the formation of
inclusion body-like structures in the cytosol of acceptor cells.
This process relies on the integrity of lysosomes, as lysosomal
pH disruption using v-ATPase inhibitors aggravates the forma-
tion of inclusion bodies. How lysosomal function is coupled to
a process that occurs in the cytosol is unclear, but lysosomal
degradation of these cytosolic structures might be essential for
homeostasis.
Exosome Fusion at the Plasma Membrane
or in Endosomes
If prionoids travel via exosomes, the cytosolic contents of exo-
somes might be released into the cytosol of the target cell by
direct fusion with the plasma membrane, or by fusion with the
limiting membrane of early endosomes after internalization. In
view of their virus-like properties, which include their budding
(Morita and Sundquist, 2004) and their contents of genetic mate-
rial (miRNA and mRNA) (Valadi et al., 2007), one wonders
whether exosomes may behave like primitive viral-like particles
that ferry molecules from one cell to the other. In fact, exosomes
contain CD9, a fusogenic protein involved in gamete fusion and
in viral fusion (The´ry et al., 1999). For each of these reasons, exo-
somes are prime candidates for the release, the extracellular
transit, and the eventual cytoplasmic delivery of prionoids.
Maybe exosomes carry amyloids on the membrane but
sequester the cytosolic amyloids inside the vesicle. If so, the
topology after fusion would be maintained. This would ensure
proper localization of the amyloids to compartments where
further conversion may occur.
Propagation of Prionoids in the Brain
In a-synucleinopathies, the pathology spreads progressively
from the canonical sites of Parkinson’s disease to remote areas
of the brain (Brundin et al., 2008). In tau pathologies, a similar
spreading occurs from the transentorhinal cortex to the hippo-
campus. In addition to the mechanisms discussed above, prio-
noids may utilize nanotubes as an extremely direct means of
propagating from cell to cell. Indeed, prions appear to hijack
tunneling nanotubes for their intercellular spreading (Gousset
et al., 2009). Even if naked a-synuclein and polyQ could enter
cells from the extracellular space, nanotubes may play a role in
the spatial spreading of pathology. At least in the case of prions,
there is strong evidence that transfer of pathology from one
neuron to another occurs transsynaptically (Glatzel et al., 2001;
Prinz et al., 2003), and a series of legendary experiments has
demonstrated progressive colonization of the entire visualNeuron 64, December 24, 2009 ª2009 Elsevier Inc. 787
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and the optical cortex after retinal prion inoculation (Fraser,
1982). The released amyloids could also be taken up by the
surrounding astrocytes and microglia network and could aid in
the expansion of the pathology. On the other hand, tau and
a-synuclein pathology occur not only in neurons but also in glia
(Park et al., 2009), suggesting that the astrocyte-microglia
network might also internalize the cytosolic amyloids. It remains
an open question whether the latter is a good or a bad thing for
the brain: microglia may be the brain’s most important defense
against prions and prionoids (Falsig et al., 2008), but conversely
could also assist in their spread (Beringue et al., 2000) (Figure 1).Conclusion
The wave of these recent reports on the prion-like behavior of
disparate pathogenic proteins raises many more questions
than it answers. Here we have highlighted a number of open
issues related to mechanisms of cell-to-cell spread of prionoids.
The resolution of such issues may constitute the first step toward
the development of rational strategies aimed at blocking trans-
cellular propagation. There is justified hope that the latter may
decelerate the progression of pathology and, consequently,
help toward fighting the devastating outcome of aggregation
proteinopathies.ACKNOWLEDGMENTS
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